Verastem Inc. Stock
Verastem Inc. Stock
Pros and Cons of Verastem Inc. in the next few years
Pros
Cons
Performance of Verastem Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Verastem Inc. | 0.990% | -1.626% | -10.370% | -11.193% | -24.961% | -19.188% | -79.542% |
| Biocryst Pharmaceuticals | 0.840% | 13.034% | 12.248% | -26.682% | -1.586% | -27.571% | -29.425% |
| Madrigal Pharmaceuticals inc. | -0.810% | -5.834% | -9.122% | 14.854% | -25.858% | 33.913% | 265.760% |
| Evolus Inc | -0.550% | 1.124% | -12.621% | -72.519% | -33.945% | -56.627% | -55.654% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Verastem, Inc. (US symbol: VSTM) operates within the Biotechnology and Medical Research industry, a sector characterized by innovation and potential growth. However, upon reviewing the company's financials, a cautious stance emerges. The financial statements present a narrative of ongoing challenges, marked by persistent losses and a struggle towards profitability. This assessment delves into the various aspects of Verastem's financial health, highlighting both the positives and negatives.
Strong Cash Position: As of December 31, 2022, Verastem had a robust cash balance of approximately $74.93 million. This liquidity can be pivotal as it provides the company with the necessary resources to fund ongoing research and development efforts or to weather economic fluctuations.
Total Assets: The total assets amounting to about $95.05 million indicate that the company has significant resources at its disposal. Having a large asset base can help in enhancing investor confidence as it contributes to the overall financial stability of the company.
Comments